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Abstract
Glutamine synthetase (GS) is ubiquitously expressed in mammalian organisms and is a key enzyme in nitrogen
metabolism. It is the only known enzyme capable of synthesising glutamine, an amino acid with many critical roles in
the human organism. A defect in GLUL, encoding for GS, leads to congenital systemic glutamine deficiency and has
been described in three patients with epileptic encephalopathy. There is no established treatment for this condition.
Here, we describe a therapeutic trial consisting of enteral and parenteral glutamine supplementation in a four
year old patient with GS deficiency. The patient received increasing doses of glutamine up to 1020 mg/kg/day.
The effect of this glutamine supplementation was monitored clinically, biochemically, and by studies of the
electroencephalogram (EEG) as well as by brain magnetic resonance imaging and spectroscopy.
Treatment was well tolerated and clinical monitoring showed improved alertness. Concentrations of plasma
glutamine normalized while levels in cerebrospinal fluid increased but remained below the lower reference
range. The EEG showed clear improvement and spectroscopy revealed increasing concentrations of glutamine
and glutamate in brain tissue. Concomitantly, there was no worsening of pre-existing chronic hyperammonemia.
In conclusion, supplementation of glutamine is a safe therapeutic option for inherited GS deficiency since it
corrects the peripheral biochemical phenotype and partially also improves the central biochemical phenotype.
There was some clinical improvement but the patient had a long standing severe encephalopathy. Earlier
supplementation with glutamine might have prevented some of the neuronal damage.
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Introduction
Glutamine synthetase (GS) is a ubiquitously expressed
cytosolic key enzyme of nitrogen metabolism [1,2]. In an
ATP-dependent manner, GS catalyzes the synthesis of
glutamine from glutamate and ammonia and is a source
for the entire body glutamine pool, since there is no net
absorption of glutamine from the intestine in healthy
individuals [3,4]. The synthesis of glutamine from GS is
the only known reaction for endogenous glutamine pro-
duction in mammals, and GS also plays an important
role in many metabolic pathways e.g. by balancing the
nitrogen pool between different compartments, by de-
toxifying ammonia and glutamate in brain astroglial cells
[5,6] or by providing osmotic cell homeostasis [6-8]. GS
is expressed in utero in early human fetuses [9] and is a
prerequisite for early development in mice and droso-
phila [10,11]. The product of the GS reaction, glutamine,
is the major amino moiety donor for other amino acids,
glucose precursors, purines and pyrimidines, and adenosine-
monophosphate [12] and is the central metabolite for
the temporary storage and transport of nitrogen between
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different organs [1]. Glutamine has a functional impact
on many metabolic processes in peripheral organs, such
as pH homeostasis in the kidney and regulation of
plasma glucose levels in the pancreas [13,14]. In the cen-
tral nervous system, glutamine is considered to be the
primary precursor of the neurotransmitter amino acids
glutamate and γ-aminobutyric acid (GABA), the most
abundant fast excitatory and inhibitory neurotransmit-
ters, respectively [15-17].
The pivotal roles of glutamine underline the import-
ance of a functional GS for normal human physiology,
so it is not surprising that patients with an inherited de-
fect of GS demonstrate a severe clinical phenotype. These
patients either died from neonatal multi-organ failure
[18,19] or, as in the case of the patient described in this
study, survived albeit suffering from severe epileptic en-
cephalopathy [20]. Unfortunately, there is no established
treatment for GS deficiency but supplementation of the
missing amino acid would be a first-thought rationale.
Glutamine supplementation has already been tested in
healthy volunteers and doses up to 750 mg/kg/d have
proved to be safe during short-term application [3,21-24].
However, since chronic hyperammonemia may be a con-
sequence of GS deficiency [20], supplying glutamine to a
patient with GS deficiency could augment ammonia
levels, potentially causing additional toxicity [25]. There-
fore, unlike therapy in the other amino acid biosynthesis
disorders [26,27], glutamine supplementation must be
carefully considered in the light of the potentially dama-
ging effects of hyperammonemia. A careful therapeutic
trial with thorough monitoring was necessary in order to
establish the safety of glutamine supplementation.
In the current study, we present a clinical trial in
the only known living GS deficient patient with severe
neurological sequelae. We demonstrate that regulated
glutamine supplementation with careful monitoring
enables correction of the biochemical defect and pro-
vides some improvement in the neurological status of
the patient.
Methods
Patient – clinical situation
The natural course of the patient has been described
previously [20]. In brief, he was born to first cousin par-
ents from Sudan after an uneventful pregnancy. At birth,
he did not need resuscitation, but soon he was noted to
have generalized hypotonia, lower limb hyperreflexia,
cloni and episodes of eye staring lasting for 2–3 minutes.
Generalized tonic-clonic convulsions started at 13 days
and, despite extended anticonvulsant therapy, epileptic
seizures persisted, contributing to a severe developmen-
tal delay. In addition, the patient demonstrated one epi-
sode of necrolytic erythema at 38 months [20] when
serum glutamine levels were< 10 μmol/L.
At the start of the therapeutic trial, the patient was
in a stuporous state with only a few episodes of ap-
parent alertness during the day that each lasted about
15 minutes. If awake, the parents were able to identify
emotional expressions such as satisfaction, hunger or
anger. He was mainly fed via his gastrostomy tube but
was also able to suck small amounts of his diet. Con-
vulsions were noted every day, but it was unclear
whether all should be classified as epileptic seizures.
Overall, the patient had a robust constitution and a
clinically intact immune system.
Before the start of the therapeutic trial, detailed clin-
ical and nutritional assessments and biochemical investi-
gations were performed at Hamad Medical Corporation,
Doha-Qatar. In an attempt to lower plasma ammonia as
much as possible before the initiation of the glutamine
therapy, the patient received increasing doses of lactu-
lose and neomycin to limit ammonia uptake from the
gut. This was done under close monitoring for dehydra-
tion and electrolyte imbalances and resulted in a short-
term decrease of plasma ammonia to 38 μmol/L. However,
as diarrhoea became troublesome, this treatment was no
longer tolerated and had to be stopped. The patient was
then hospitalized for four weeks ensuring close clinical,
laboratory and technical monitoring. The parents of the
patient consented to the therapeutic trial which was per-
formed at the University Children’s Hospital Zurich. The
study was approved by the responsible institutional re-
view board (Kantonale Ethikkommission).
Biochemical investigations at baseline and during
monitoring
Before glutamine supplementation was initiated, baseline
metabolic and endocrinologic investigations were done
in blood (including fasting plasma amino acid profile,
ammonia, growth hormone, thyroid function, vitamins
A, E, D and B12, and essential fatty acids) and in cere-
brospinal fluid (CSF) (including amino acid profile, free
and total GABA, neurotransmitter metabolites, folates,
pterines, creatine, guanidinoacetate), in addition to routine
biochemical parameters (such as blood count, serum
electrolytes, creatinine, ASAT, and ALAT). Amino acid
analysis in plasma and CSF was done applying the clas-
sical method based on ion exchange chromatography
with post column derivatization with ninhydrin using
the Biochrom 30+ analyzer (Biochrom, Cambridge, UK).
Most metabolic parameters (including tests in CSF) were
done weekly, but fasting plasma ammonia and amino
acid profiles were obtained daily.
Technical investigations at baseline and during monitoring
EEG examinations were recorded both in the awake and
sleeping state at baseline and at weekly intervals during
trial monitoring.
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Cerebral magnetic resonance imaging (MRI) and spec-
troscopy (MRS) studies were performed with a 3 T GE
HD.xt MRI scanner (GE Healthcare, Waukesha, WI,
USA). The imaging protocol included one axial T1
weighted sequence (repetition time TR= 620 ms; echo
time TE= 21 ms), T2 weighted sequences in 3 planes
(TR= 9300 ms; TE = 96 ms), FLAIR (TR= 9300 ms;
TE = 124 ms; inversion time TI = 2250 ms), diffusion
weighted images DWI (35 gradient directions and
b_value= 700 s/mm2, voxel = 0.8 x 0.8 x 2.5 mm3) and a
T1 weighted sequence after intravenous Gadolinium
injection.
Single voxel [1H]MRS spectra were acquired from a
voxel of interest in the left basal ganglia (15x15x15 mm3),
using a point-resolved spectroscopy (PRESS) sequence
with repetition time (TR) = 3000 ms and echo time
(TE) = 35 ms. In order to examine the cerebral concen-
trations of GABA, glutamate, and glutamine in more de-
tail, additional edited spectra were acquired from a
25x40x25 mm3 voxel of interest (VOI) in the left
basal ganglia using a MEGA-PRESS sequence [28]
with TR = 1800 ms, TE = 68 ms. For each metabolite
spectrum, 16 water reference lines were also acquired as
part of the standard PROBE acquisition. Metabolite con-
centrations were derived with LCModel version 6.1-4 F
[29], using the unsuppressed water signal as an internal
calibration standard. Following this method, the spec-
trum was modeled as a linear combination of basis spectra
from in vitro metabolite solutions of known concentra-
tion, (see reference [29] for further details). Since this
method incorporates the full multiplet peak profiles for
glutamate and glutamine, the relative contributions from
these neurotransmitters can be resolved despite their
overlapping peaks. Brain MRI and MRS studies were
repeated after 2 and 4 weeks, respectively. For compari-
son, the same MRS protocol was applied in three age-
matched comparison subjects, referred for MRI for skull
malformation, developmental delay, and epilepsy, re-
spectively, with normal cerebral MR imaging.
Glutamine supplementation
L-glutamine was provided as a powder (ResourceW Glu-
tamin, Nestlé Nutrition, Vevey, Switzerland). A low starting
regime of 17 mg/kg/d divided in eight dosages was
chosen because of concerns about the possible toxicity
of raising ammonia and glutamate levels. Glutamine was
then increased step-wise each day to a final dose of
1020 mg/kg/on day 21 of the trial. Since fasting glutam-
ine levels did not increase during the first two weeks of
the trial, the interval between single dosages was shor-
tened to two hours (Figure 1). To facilitate the treat-
ment, 330 mg/kg glutamine was administered from
12 p.m. until 8 a.m. as a continuous enteral infusion via
the gastrostomy tube after dilution in 100 ml water.
Prior to this infusion, the stability of the glutamine solu-
tion was confirmed by measurement of glutamine at 0, 6
and 9 hours, which yielded steady concentrations (data
not shown). To provide information on the parenteral
dose of glutamine needed for maintaining normalized
plasma glutamine levels, L-glutamine (DipeptivenW,
Fresenius Kabi, Stans, Switzerland) was given as a con-
tinuous infusion over six hours at a rate of 21 and
31 mg/kg/h, respectively, and over eight hours at a rate
of 41 mg/kg/h while enteral glutamine supplementation
was paused.
Results
Clinical situation
The therapeutic trial lasted for four weeks. On one oc-
casion the patient suffered from a catheter-associated
infection requiring targeted intravenous antibiotics
(amoxicillin clavulanate, gentamicin). However, the pa-
tient remained clinically stable throughout this four
week period.
Figure 1 Glutamine dosing regimen and plasma concentrations during the 4 weeks trial. Glutamine was initially given 8 doses per day
(blue line) but switched to 12 doses per day (blue dotted line) after 14 days treatment. Fasting plasma glutamine concentrations are given (with
red ▪) as obtained every morning and for CSF glutamine concentrations (with turquoise ) illustrating the increase in plasma and CSF glutamine
concentrations, respectively, under glutamine supplementation.
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Two weeks after the start of glutamine supplementa-
tion, the plasma glutamine concentrations increased
with a concomitant improvement in the patient’s alert-
ness. This increased alertness was noted by the parents
but also by staff members based on prolonged awake
phases. In addition, the intensity of smiling of the pa-
tient improved resulting in his “longest ever smile” on
the last day of the trial as described by the father.
Both enteral and parenteral L-glutamine supplementa-
tion was tolerated during the four week trial without
side effects. However, when the patient returned to his
home country, the parents noticed an increased irritability.
Since this was attributed to L-glutamine supplementation,
the dose of glutamine was reduced again, however, with-
out accurate documentation.
Monitoring of biochemical parameters
Considerable concern was focused on the levels of am-
monia and glutamate, which remained stable in blood as
well as in CSF (Table 1). Fasting concentrations of
plasma glutamine were 74 μmol/L (reference range
457–857) at the start of the trial, remaining stable while
glutamine was given every three hours, but increasing
above the lower limit of normal when glutamine was
given at a dose of 700 mg/kg/d at a two hourly interval
(Figure 1). There was no clear decrease of plasma glu-
tamine related to the catheter-associated infection, but
this might have escaped our only once-daily monitoring.
Levels of CSF glutamine constantly increased from 121
at baseline to 146, 171 and 201 μmol/L (reference range
333–658) after 2, 3, and 4 weeks of treatment, respect-
ively, but remained below the lower limit of normal in
this limited trial period (Table 1 and Figure 1).
Concentrations of creatine and guanidinoacetate in
CSF were normal in this patient both at baseline and at
the end of the trial. However, baseline creatine was in
the upper normal range and showed a similar decrease
to that observed by MRS. CSF concentrations of homo-
vanillic acid (171 and 188 nmol/L, respectively, reference
range 211–871) were unchanged during the trial. Levels
of CSF folates and pterines were normal (data not
shown) as were concentrations of glutamate and total as
well as free GABA both before and at the end of the trial
(Table 1).
Monitoring of EEG, MRI and MRS
EEGs recorded at baseline were severely abnormal with
frontal high amplitude slow waves (0.5-2/s) and intermit-
tent generalized subdelta (0.5/s) waves. During sleep,
amplitude was intermittently attenuated in irregular in-
tervals and partly suppressed for 1–3 seconds. Multifocal
sharp waves were present when awake and more fre-
quently when asleep. EEG after 1 week of treatment
showed a slightly improved background activity and the
Table 1 Relevant biochemical and MRS investigations at baseline and after four weeks glutamine supplementation
Parameter Baseline End of trial Reference range
Blood
Ammonia (μmol/L) 66 76 12-48
Glutamine (μmol/L) 74 731 457–857
Glutamate (μmol/L) 58 28 17-69
CSF
Ammonia (μmol/L) 71 75 12-48
Glutamine (μmol/L) 121 201 333–658
Glutamate (μmol/L) <2.5 <2.5 0–5
Homovanillic acid (nmol/L) 171 188 211–871
Creatine (μmol/L) 84 56 17–87
Free GABA (μmol/L) 0.030 0.037 0.032-0.167
Total GABA (μmol/L) 8.3 7.47 3.3-12.2
Basal ganglia MRS Reference values from age-matched comparison subjects (n = 3)
NAA (IU) 4.2 4.6 8.3-8.8
Creatine + phosphocreatine (IU) 12.0 10.5 8.4-8.6
Choline (IU) 3.6 2.9 1.7-2.0
Myo-inositol (IU) 6.7 6.4 3.0-4.0
Glutamate (IU) 4.6 4.9 7.3-10.3
Glutamine (IU) 0 1.4 3.1-6.3
GABA (IU) 3.0 2.6 2.4-3.7
Pathological values in bold; GABA: γ-aminobutyric acid; NAA: N-acetylaspartate.
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intermittent amplitude attenuation during sleep seemed
to be less distinct. After 3 weeks of glutamine treatment
the background activity had clearly improved with dom-
inant 3-5/s activity in the awake state. After 4 weeks,
intermittent amplitude attenuations completely disap-
peared during sleep and multifocal sharp waves were less
frequent both awake and asleep (Figure 2).
The baseline MRI (performed at age 3 9/12 years)
showed changes that were not present in the previous
examination at 11 months [20], including increased white
matter signal intensity on T2 weighted images, prominent
Virchow-Robin-spaces, reduced white matter volume with
consequent thinning of the corpus callosum and second-
ary enlargement of CSF spaces (see Figure 3). The basal
ganglia were atrophic and no contrast enhancement was
present. The two following MRI exams did not show fur-
ther changes (data not shown).
At baseline, MRS demonstrated undetectable gluta-
mine, reduced N-acetylaspartate (NAA) and glutamate
and elevated creatine, choline, and myo-inositol (mI).
Monitoring after two weeks revealed increased glutam-
ine and glutamate levels and a decrease of creatine and
choline with a modest increase in NAA. After four
weeks, glutamine, glutamate, and NAA levels continued
to increase but remained below normal. Creatine and
choline levels continued to decrease but remained above
normal. GABA levels decreased during the trial but
remained within the normal range (Figure 4).
Discussion
Glutamine supplementation is well tolerated and partially
rescues the biochemical phenotype
With this study, we provide the first report of a thera-
peutic trial for a patient with congenital GS deficiency.
The patient is the only known living patient with this
disorder [20], as the two other patients previously re-
ported [18,19] did not survive beyond the neonatal age,
rendering any therapy impossible. A plausible but not
proven explanation for the survival of this patient would
be the assumption of a slightly higher level of GS re-
sidual activity due to another missense mutation of the
GLUL gene (p.Arg324Ser in the case of the present pa-
tient [20]; p.Arg324Cys and p.Arg341Cys in the case of
the neonatally deceased patients [18]). Supplementation
Figure 2 EEG before and at the end of the therapeutic trial. EEG recordings before supplementation of glutamine (2a,b) and at the end of
the therapeutic trial (2c,d) showing the significant improvement of the background activity and the reduction of multifocal sharp waves both in
the awake state (2c) and during sleep (2d).
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Figure 3 MRI investigations. T2 weighted images obtained at age 11 months (left column) and at the beginning of the therapeutic trial (at age
3 9/12 years; right column) illustrating the severe brain atrophy caused by loss of cerebral white matter with consequent thinning of the corpus callosum.
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of an amino acid has already been successfully applied in
other amino acid biosynthesis disorders, both in a pro-
phylactic approach during pregnancy and in a thera-
peutic way postnatally [26,27,30]. Thus, supplementation
of L-glutamine is a logical therapeutic approach, but was
burdened with concerns about possible increases in am-
monia and extracellular glutamate concentrations, poten-
tially leading to neurotoxicity and increased susceptibility
to seizures [31].
As the main result of this trial, the intervention was
well tolerated and allowed the normalization of the peri-
pheral biochemical phenotype of GS deficiency, as de-
monstrated by normal plasma glutamine levels under
high-dose glutamine supplementation (1020 mg/kg/d).
This observation confirms earlier reports that while at
normal levels of intake there is no net absorption of glu-
tamine in the intestine of healthy individuals, additional
supplementation does increase plasma glutamine con-
centrations [3,21,32]. However, in GS deficiency there is
presumably some net absorption at lower levels of glu-
tamine intake. In addition, the central biochemical phe-
notype could be substantially improved, as demonstrated
by enhanced glutamine availability in CSF and brain tis-
sue. Brain MRS based quantification of glutamine yielded
concentrations that continuously increased from zero to
measurable levels, albeit still below the findings seen in
age-matched comparison subjects. MRS glutamate was
also low at baseline, increasing during the trial but still
remaining low relative to typical levels. Since MRS mea-
surements of glutamate, glutamine and GABA do not
provide information concerning their subcellular loca-
lisation, it is not known if the increases in glutamine and
glutamate detected with MRS reflect changes in the
neurotransmitter pools of these metabolites or to changes
in metabolic pools. However, the lack of a further accu-
mulation of glutamine in brain tissue is consistent with
an increase in utilisation. Lack of total restoration of the
biochemical phenotype in the CNS may partially be due
Figure 4 MRS investigations. Brain MRS obtained from the patient at baseline (4a, d) and at the end of the therapeutic trial (4b,e). In addition,
an average spectrum from 3 comparison subjects is shown (4c, f). Note the absence of Gln (glutamine) at baseline (4a, d) and the increase of
Glu +Gln (glutamate and glutamine) at the end of the trial (4b,e). Figures 4a-c show the spectra acquired with the standard PRESS sequence, and
figures 4d-f show the MEGA-PRESS data.
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to brain atrophy as shown in the basal ganglia by MRI.
Atrophy and/or neurodegeneration are also supported by
the low levels of NAA and the elevated levels of creatine
and choline demonstrated by MRS and CSF measurements.
In normal subjects, the glutamine transporter SN1
(SLC38A3) at the astroglial membranes maintains glu-
tamine concentrations in the extracellular fluid around
0.4 mM by bidirectional glutamine transport [33,34].
With a dysfunctional GS the astroglial cells no longer
produce glutamine and their contribution to the ex-
tracellular glutamine homeostasis is abolished. With
glutamine supplementation, glutamine will cross the
blood–brain barrier and increase the levels of glutamine
in the perisynaptic extracellular compartments [35]. Many
of the neuronal glutamine transporters - including the
unidirectional system A transporters SAT1 (SLC38A1)
and SAT2 (SLC38A2) shown to be fundamental for
neurotransmitter generation [17,36,37] - have Km values
in the order of 0.2-2.3 mM for glutamine [38,39]. These
transporters will be stimulated by the increased supply
of glutamine, enabling the neurons to accumulate glu-
tamine continuously and facilitating the catabolism of
glutamine to sustain synthesis of the neurotransmitters
glutamate and GABA [36]. Thus, lack of further build-
up of glutamine in brain tissue and in CSF is consistent
with its increased utilization. Furthermore, our data sug-
gest that glutamine supplementation counteracts the im-
balance in glutamatergic and GABAergic drive described
in some forms of epilepsy [40] and we speculate that this
might form the basis of the improvement in the back-
ground EEG activity, reflecting the clinical amelioration
of the encephalopathy. Thus, our data show that gluta-
mine supplementation succeeded in increasing the
supply of glutamine throughout the body, possibly
stimulating cellular metabolism and sustaining normal
function.
Glutamine supplementation does not aggravate
hyperammonemia
As demonstrated in this study, levels of plasma and CSF
ammonia remained stable even when glutamine supple-
mentation was increased to the maximum of 1020 mg/kg/d.
The slightly higher plasma ammonia concentrations at
the end of the trial are likely attributed to the infection,
as concomitant CSF ammonia levels remained unchanged
in comparison to baseline levels (Table 1). Our results
correspond well to data gained from genetic disruption
of GS in mice which show a modest increase (1.6 fold)
in cortical ammonia levels [41]. However, in addition, we
show that a therapeutic intervention with glutamine
supplementation does not exacerbate the levels of plas-
ma and CSF ammonia in a human. Unfortunately, there
was no close monitoring of ammonia (or amino acid
profiles) after the discharge of the patient from the
hospital when he developed irritability, so no conclu-
sions can be drawn with regard to the cause of this
irritability.
Glutamine is critically needed during pregnancy, in the
neonatal and early childhood periods
The severe changes in cerebral white matter at the be-
ginning of the therapeutic trial (Figure 3) demonstrate
that the brain of the patient has probably deteriorated
over the years due to glutamine deficiency and lack of
its metabolic products, and due to severe epileptic en-
cephalopathy. This observed neurodegeneration is con-
sistent with experimental findings supporting the role of
GS for Schwann cell differentiation [42]. During preg-
nancy, there is a great need for glutamine for normal
ontogeny and brain development [43,44] and there is
GS-dependent de novo synthesis of glutamine in the
placenta [45]. As the glutamine transporters on the pla-
centa are also upregulated to transport glutamine ac-
tively from the maternal circulation to the fetus the
demand may be partially met by increased extraction of
glutamine from the maternal circulation [46]. However,
this supply is abolished after birth, while the demand for
glutamine – e.g. for glutamate and GABA formation and
myelination - continues to increase due to synaptogenesis
and establishment of functional neuronal networks [47].
Substantial clinical improvement in the patient’s con-
dition was therefore unlikely. However, the improvement
in alertness of the patient, although difficult to quantify
for external evaluation, can be considered as encour-
aging with respect to an earlier start of treatment in fu-
ture patients. Likewise, EEG recordings were much
improved both in the awake and sleeping state, suggest-
ing that external glutamine can cross the blood brain
barrier and possibly influence neuronal activity. Of note,
enteral glutamine supplementation was sufficient to es-
tablish and maintain normal plasma glutamine levels. As
an alternative if enteral use is not feasible, parenteral ap-
plication was also possible in this patient but was con-
sidered as a second choice given the higher invasiveness.
Conclusions
In summary, this is the first report of a therapeutic in-
tervention in a patient with an inherited defect of GS,
demonstrating the feasibility of correcting systemic glu-
tamine deficiency in this disorder without worsening
pre-existing hyperammonemia or provoking toxic CSF
glutamate levels. For future patients, glutamine supple-
mentation should begin as early as possible in order to
elucidate to what extent earlier intervention can prevent
the devastating natural course of chronic encephalop-
athy in GS deficiency. In fact, since glutamine is a func-
tionally essential amino acid also in healthy persons,
adequate maternal production and supply of glutamine
Häberle et al. Orphanet Journal of Rare Diseases 2012, 7:48 Page 8 of 10
http://www.ojrd.com/content/7/1/48
to the fetal circulation may be a limiting factor in par-
ticular in the presence of GS deficiency in the placenta.
Thus, glutamine supplementation may have beneficial
outcomes during pregnancy for a child with GS defi-
ciency and should be considered. Since newborn screen-
ing programs will probably not adopt GS deficiency as a
target disease based on its extremely low incidence and
on the instability of glutamine in dried blood samples, a
high awareness towards low glutamine levels found in
selective screening is needed. Moreover, additional re-
search is warranted to make headway towards ameliora-
ting the effects of this devastating condition as well as to
improve outcomes for this rare genetic disease.
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